Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

In a dynamic environment, an expert shares insights into potential AI applications in the clinical research setting at OCT ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.

The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...

Biopharmaceutical company Cullinan Therapeutics is due to begin a trial of its drug candidate CLN-978 for treating Sjögren’s ...

Pacira BioSciences has revealed that PCRX-201 has demonstrated improvements in individuals with knee osteoarthritis in a ...

The World Health Organization estimates that 50% of vaccines are wasted globally each year due to cold chain issues.